Abiopharma

🔍 Blume-Jensen Peter (Executive)

Company: Acrivon Therapeutics, Inc. (ACRV)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Sold 14,036 shares of Common Stock at $2.2064 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: false | shares_owned_after: 2,230,052.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 385,859.00 | Footnotes: F4

Footnotes:

• F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
• F2: The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4.
• F3: These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
• F4: These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.